Download internationale vereinigung der pharmaberater

UNION INTERNATIONALE DES ASSOCIATIONS DE DÉLÉGUÉS MÉDICAUX
INTERNATIONAL UNION OF MEDICAL ADVISERS ASSOCIATIONS
UNIÓN INTERNACIONAL DE ASOCIACIONES DE VISITADORES MÉDICOS
INTERNATIONALE VEREINIGUNG DER PHARMABERATER - VERBÄNDE
INTERNATIONALE UNION DER ÄRZTEBESUCHER VEREINIGUNGEN
ΔΙΕΘΝΗΣ ΕΝΩΣΗ ΣΥΛΛΟΓΩΝ ΙΑΤΡΙΚΩΝ ΕΠΙΣΚΕΠΤΩΝ
UIADM
PRESS RELEASE
The 23rd International Congress of U.I.A.D.M. took place on 4-6/12/2009, in a time
that world community confronts the biggest economic crisis after World War II and in a very
competitive environment, both at a European and at an international level.
The Congress examined the situation that prevails today in the sector of Drug, both
internationally and in every individual country, as the circumstances have been shaped
because of the global economic crisis as well.
Phrmaceutical research, as it has been evolved during the last decades, has probably
reached its limits regarding conventinal drugs and is oriented, in conjunction with biomedical
technology, to a specialized targeting.
This is the reason why we see accumulations of funds and mergers of companies, in
order to support research, whose cost today is very high, and also to retain the market shares
by promoting research and work positions.
The accomodation from the conventional pharmaceutical access to the biomedical
plarmaceutical answer is inevitable, not only in terms of economic survical, but also as a
strategically planned solution for the promotion of health. The drug market is currently
balanced, despite the negative symbolisms which is a certain result of mergers and high
accumulation of funds. We see, however, that work positions become fewer and fewer, both
internationally and in the national markets.
On the other hand, the states, unable to absorb these changes, turn to measures that
limit health expenses. The market compensation mechanisms that are being deceloped at a
national level cannot absorb these changes, which are “imposed” socially and economically.
Χαλκοκονδύλη 56 – 10432 ΑΘΗΝΑ – Τηλ.: 210-52.24.070, 210-52.35.331 – Fax: 210-52.35.331
56, Halkokondili st., Athens 10432 Hellas, Tel.: +30.210.52.24.070, +30.210-52.35.331 – Fax: +30.210-52.35.331
www.uiadm.org
- e-mail: [email protected]
For this reason, the states bring into play mechanistic means that only serve the budgets and
the balance sheets of the states for the particular period in which the negative financial sizes
appeared. We have seen such measures from time to time in various countries, but they do not
have any permanent financial result:

Positive or negative lists of drugs

Tenders for the procurement of supplies to Hospitals and Insurance Funds

Contribution of the insured persons into the medication cost

O.T.C.

Support of productive procedures for the generics

Redecution of prices

Prescription control, etc.
People working in Drug often face unfair attacks and denigrations from the Media or
other sectors, exactly because we serve a domain which is socially sensitive and economically
demonized.
The main target for these derogatory “social” refereneces is usually the Medical
Adviser. Due to the nature of our profession, we are the main link that connects
pharmaceutical research and technology with the practice of clinical medicine, in order to
promote public health. On the other hand, we transfer our clinical observations and the
everyday applications of medical pharmaceutical practice to the pharmaceutical companies,
among others.
This valuable link has strong scientific, sopcial and economicc bonds and is therefore
by default necessary in this demarkated envirionment. Human intervention in this process is
not a simple economic procedure that could be done by any technical or other means; it is the
main catalyte, the feedback from research and drug titration to the simple everyday medical
practice, and vice versa
The continuous and objective supply of information to healthcare professionals
on the rational use of drugs, the patient’s compliance with the instructions of the
attending physician and the systematic monitoring of an integrated system of healthcare
services can contribute decisively to the significant reduction of health expenses (by
saving huge financial resources) and, what’s most important, to the limation of mistakes
from the misuse of drugs that, at a large extent, are fatal for the user-patient himself.
According to the Federal Institute for Drugs BfArM Germany, 160,000 people
are admitted every year into the Hospitals due to drug misuse while another 20,000 die
of the same cause. According to the University of Rostock, these numbers amount to
250,000 and 40,000 respectively.
The general directions towards which the new Board of U.I.A.D.M will work were
submitted and voted in the Congress. These directions are:
Α. Contacts and establishment of cooperation and dialogue with all European
and international bodies that are connected to Drug and Health, ass well as with
agencies of social organizations.
1. European and international labour office
2. World Health Organization
3. European Union (Health Commissioner and Commissions, Sector of Social
Affairs, etc.)
4. EFPIA and IFPIA
5. Central associations of physicians and pharmacists, etc.
Β. Establishment of a single framework and certification of the profession in the
European Union.
C. Support and promotion of pharmacovigilance through the ongoing
information and control of all of the involved parties.
The 23rd Congress has elected the new Board, which is as follows:
President:
KONIDARIS GERASSIMOS (GR)
Substitute President:
WOLFGANG VOGEL (DE)
Vice President:
OSCAR MARIO RILO CASTRO (ES)
Vice President:
VASSILIADES ANDREAS (CY)
Secretary General:
SCHEMBRI DORIAN (MT)
Sub. Secretary General:
DESPINA TIRTEA (RO)
Treasurer:
NIKOLAIDES GREGORIS (CY)
PRESS & PUBLIC RELATIONS SECRETARIAT